Scotia Pharmaceuticals' Foscan To Enter Trials Soon

17 March 1997

- A trial program is expected to begin with Scotia Pharmaceuticals'photosensitizing agent Foscan for the treatment of recurrent head and neck cancer in the USA in the near future. This follows approval of its Investigational New Drug application by the US Food and Drug Administration last year (Marketletter December 23, 1996). Data from ongoing Phase III trials will be used to form a dossier which will be submitted to the European authorities in fourth-quarter 1997. According to the company, with Foscan it is now possible to treat thicker tumors than before, using just a portable diode laser. Scotia is also investigating the use of Foscan in other cancers, including prostate, brain, esophagus and stomach. More information will be reported following a meeting to be held in London on March 25.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >

Today's issue

Company Spotlight

Ironwood is a US-based biotech advancing a pipeline of medicines in multiple areas of significant unmet need, including irritable bowel syndrome with constipation ((IBS-C)/chronic idiopathic constipation (CIC), vascular and fibrotic diseases, and refractory gastroesophageal reflux disease, among others.